131 related articles for article (PubMed ID: 16150928)
1. A novel group of genes regulates susceptibility to antineoplastic drugs in highly tumorigenic breast cancer cells.
Mallory JC; Crudden G; Oliva A; Saunders C; Stromberg A; Craven RJ
Mol Pharmacol; 2005 Dec; 68(6):1747-56. PubMed ID: 16150928
[TBL] [Abstract][Full Text] [Related]
2. Altered expression of proliferation-inducing and proliferation-inhibiting genes might contribute to acquired doxorubicin resistance in breast cancer cells.
Saleh EM; El-Awady RA; Abdel Alim MA; Abdel Wahab AH
Cell Biochem Biophys; 2009; 55(2):95-105. PubMed ID: 19593673
[TBL] [Abstract][Full Text] [Related]
3. cDNA microarray analysis of isogenic paclitaxel- and doxorubicin-resistant breast tumor cell lines reveals distinct drug-specific genetic signatures of resistance.
Villeneuve DJ; Hembruff SL; Veitch Z; Cecchetto M; Dew WA; Parissenti AM
Breast Cancer Res Treat; 2006 Mar; 96(1):17-39. PubMed ID: 16322897
[TBL] [Abstract][Full Text] [Related]
4. Gene expression profiling revealed survivin as a target of 3,3'-diindolylmethane-induced cell growth inhibition and apoptosis in breast cancer cells.
Rahman KW; Li Y; Wang Z; Sarkar SH; Sarkar FH
Cancer Res; 2006 May; 66(9):4952-60. PubMed ID: 16651453
[TBL] [Abstract][Full Text] [Related]
5. Prediction of doxorubicin sensitivity in breast tumors based on gene expression profiles of drug-resistant cell lines correlates with patient survival.
Györffy B; Serra V; Jürchott K; Abdul-Ghani R; Garber M; Stein U; Petersen I; Lage H; Dietel M; Schäfer R
Oncogene; 2005 Nov; 24(51):7542-51. PubMed ID: 16044152
[TBL] [Abstract][Full Text] [Related]
6. Evasion of a single-step, chemotherapy-induced senescence in breast cancer cells: implications for treatment response.
Elmore LW; Di X; Dumur C; Holt SE; Gewirtz DA
Clin Cancer Res; 2005 Apr; 11(7):2637-43. PubMed ID: 15814644
[TBL] [Abstract][Full Text] [Related]
7. Cell-type-specific responses to chemotherapeutics in breast cancer.
Troester MA; Hoadley KA; Sørlie T; Herbert BS; Børresen-Dale AL; Lønning PE; Shay JW; Kaufmann WK; Perou CM
Cancer Res; 2004 Jun; 64(12):4218-26. PubMed ID: 15205334
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer cells response to the antineoplastic agents cisplatin, carboplatin, and doxorubicin at the mRNA expression levels of distinct apoptosis-related genes, including the new member, BCL2L12.
Thomadaki H; Scorilas A
Ann N Y Acad Sci; 2007 Jan; 1095():35-44. PubMed ID: 17404015
[TBL] [Abstract][Full Text] [Related]
9. Increased cellular accumulation and distribution of amrubicin contribute to its activity in anthracycline-resistant cancer cells.
Mamidipudi V; Shi T; Brady H; Surapaneni S; Chopra R; Aukerman SL; Heise C; Sung V
Cancer Chemother Pharmacol; 2012 Apr; 69(4):965-76. PubMed ID: 22120960
[TBL] [Abstract][Full Text] [Related]
10. Agonist and antagonist of retinoic acid receptors cause similar changes in gene expression and induce senescence-like growth arrest in MCF-7 breast carcinoma cells.
Chen Y; Dokmanovic M; Stein WD; Ardecky RJ; Roninson IB
Cancer Res; 2006 Sep; 66(17):8749-61. PubMed ID: 16951191
[TBL] [Abstract][Full Text] [Related]
11. Role of DNA hypomethylation in the development of the resistance to doxorubicin in human MCF-7 breast adenocarcinoma cells.
Chekhun VF; Kulik GI; Yurchenko OV; Tryndyak VP; Todor IN; Luniv LS; Tregubova NA; Pryzimirska TV; Montgomery B; Rusetskaya NV; Pogribny IP
Cancer Lett; 2006 Jan; 231(1):87-93. PubMed ID: 16356834
[TBL] [Abstract][Full Text] [Related]
12. Expression profiles of apoptotic genes induced by curcumin in human breast cancer and mammary epithelial cell lines.
Ramachandran C; Rodriguez S; Ramachandran R; Raveendran Nair PK; Fonseca H; Khatib Z; Escalon E; Melnick SJ
Anticancer Res; 2005; 25(5):3293-302. PubMed ID: 16101141
[TBL] [Abstract][Full Text] [Related]
13. Gene expression changes during the development of estrogen-independent and antiestrogen-resistant growth in breast cancer cell culture models.
Pennanen PT; Sarvilinna NS; Ylikomi TJ
Anticancer Drugs; 2009 Jan; 20(1):51-8. PubMed ID: 19343000
[TBL] [Abstract][Full Text] [Related]
14. Over-expression of ERp29 attenuates doxorubicin-induced cell apoptosis through up-regulation of Hsp27 in breast cancer cells.
Zhang D; Putti TC
Exp Cell Res; 2010 Dec; 316(20):3522-31. PubMed ID: 20833165
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of Stat3 increases doxorubicin sensitivity in a human metastatic breast cancer cell line.
Gariboldi MB; Ravizza R; Molteni R; Osella D; Gabano E; Monti E
Cancer Lett; 2007 Dec; 258(2):181-8. PubMed ID: 17920763
[TBL] [Abstract][Full Text] [Related]
16. Hpr6 (heme-1 domain protein) regulates the susceptibility of cancer cells to chemotherapeutic drugs.
Crudden G; Chitti RE; Craven RJ
J Pharmacol Exp Ther; 2006 Jan; 316(1):448-55. PubMed ID: 16234411
[TBL] [Abstract][Full Text] [Related]
17. Identification of 5-fluorouracil-inducible target genes using cDNA microarray profiling.
Maxwell PJ; Longley DB; Latif T; Boyer J; Allen W; Lynch M; McDermott U; Harkin DP; Allegra CJ; Johnston PG
Cancer Res; 2003 Aug; 63(15):4602-6. PubMed ID: 12907638
[TBL] [Abstract][Full Text] [Related]
18. Molecular profile and cell cycle in MCF-7 cells resistant to cisplatin and doxorubicin.
Lukyanova NY; Rusetskya NV; Tregubova NA; Chekhun VF
Exp Oncol; 2009 Jun; 31(2):87-91. PubMed ID: 19550397
[TBL] [Abstract][Full Text] [Related]
19. Patterns and changes in gene expression following neo-adjuvant anti-estrogen treatment in estrogen receptor-positive breast cancer.
Cappelletti V; Gariboldi M; De Cecco L; Toffanin S; Reid JF; Lusa L; Bajetta E; Celio L; Greco M; Fabbri A; Pierotti MA; Daidone MG
Endocr Relat Cancer; 2008 Jun; 15(2):439-49. PubMed ID: 18508997
[TBL] [Abstract][Full Text] [Related]
20. Hypoxia-induced resistance to cisplatin and doxorubicin in non-small cell lung cancer is inhibited by silencing of HIF-1alpha gene.
Song X; Liu X; Chi W; Liu Y; Wei L; Wang X; Yu J
Cancer Chemother Pharmacol; 2006 Dec; 58(6):776-84. PubMed ID: 16532342
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
